Alyamani M.
53
Coauthors
6
Documentos
Volumen de publicaciones por año
Cargando gráfico
| Año de publicación | Num. Publicaciones |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2020 | 1 |
Publicaciones por áreas de conocimiento
Cargando gráfico
| Área de conocimiento | Num. Publicaciones |
|---|---|
| Cáncer | 6 |
| Farmacología | 3 |
| Bioquímica | 3 |
| Descubrimiento de fármacos | 2 |
| Química analítica | 1 |
Publicaciones por áreas temáticas
Cargando gráfico
| Área temática | Num. Publicaciones |
|---|---|
| Farmacología y terapéutica | 3 |
| Enfermedades | 3 |
| Química analítica | 1 |
| Fisiología humana | 1 |
| Bioquímica | 1 |
Principales fuentes de datos
| Origen | Num. Publicaciones |
|---|---|
| Scopus | 6 |
| Google Scholar | 0 |
| RRAAE | 0 |
Cargando gráfico
Coautores destacados por número de publicaciones
| Coautor | Num. Publicaciones |
|---|---|
| Richard J. Auchus | 6 |
| Sharifi N. | 6 |
| Upadhyay S.K. | 5 |
| Li Z. | 4 |
| Garcia J. | 2 |
| Berk M.P. | 2 |
| Li J. | 2 |
| O'Day P.J. | 1 |
| Wright C. | 1 |
| Dreicer R. | 1 |
Cargando gráfico
Top Keywords
Cargando gráfico
Publicaciones del autor
Abiraterone acetate treatment lowers 11-oxygenated androgens
ArticleAbstract: Context: The human adrenal is the dominant source of androgens in castration-resistant prostate cancPalabras claves:Autores:Alyamani M., O'Day P.J., Richard J. Auchus, Sharifi N., Wright C.Fuentes:scopusDevelopment and validation of a novel LC–MS/MS method for simultaneous determination of abiraterone and its seven steroidal metabolites in human serum: Innovation in separation of diastereoisomers without use of a chiral column
ArticleAbstract: Abiraterone acetate (AA), the prodrug of abiraterone, is FDA-approved for the treatment of castratioPalabras claves:abiraterone, LC–MS/MS, Metabolites, Method validation, Prostate cancerAutores:Alyamani M., Anderson D., Li Z., Richard J. Auchus, Sharifi N., Upadhyay S.K.Fuentes:scopusSteroidogenic Metabolism of Galeterone Reveals a Diversity of Biochemical Activities
ArticleAbstract: Galeterone is a steroidal CYP17A1 inhibitor, androgen receptor (AR) antagonist, and AR degrader, undPalabras claves:3βHSD, abiraterone, Androgens, CYP17A1, galeterone, metabolism, Prostate cancer, steroidsAutores:Alyamani M., Berk M.P., Li J., Li Z., Richard J. Auchus, Sharifi N., Tang J., Upadhyay S.K.Fuentes:scopusConversion of abiraterone to D4A drives anti-tumour activity in prostate cancer
ArticleAbstract: Prostate cancer resistance to castration occurs because tumours acquire the metabolic capability ofPalabras claves:Autores:Alyamani M., Bishop A., Bunch D., Dreicer R., Garcia J., Li Z., Liu J., Richard J. Auchus, Sharifi N., Upadhyay S.K.Fuentes:scopusRedirecting abiraterone metabolism to fine-tune prostate cancer anti-androgen therapy
ArticleAbstract: Abiraterone blocks androgen synthesis and prolongs survival in patients with castration-resistant prPalabras claves:Autores:Abazeed M., Alyamani M., Balk S., Li J., Li Z., Richard J. Auchus, Rogacki K., Sharifi N., Taplin M., Upadhyay S.K.Fuentes:scopus